FASTBASE SOLUTIONS

“Decision with Precision”

News and Publications

FASTBASE SOLUTIONS was granted the phase 1SME Instrument as well as the EU Seal of Excellence

#
#
Time resolved amplified FRET identifies protein kinase B activation state as a marker for poor prognosis in clear cell renal cell carcinoma Author links open overlay panel
BBA Clinical 8 (2017) 97–102

James Miles, Christopher J. Applebee, Pierre Leboucher, Sonia Lopez-Fernandez, Dae-Jin Lee, Rosa Guarch, Stephen Warde Peter J. Parker, Jose I. López, Banafshé Larijani (2017)

#
Uncoupling TORC2 from AGC kinases inhibits tumour growth.
Oncotarget August 2017 DOI: 10.18632/oncotarget.20086

Angus J.M. Cameron, Selvaraju Veeriah, Jacqueline J.T. Marshall, Elizabeth R. Murray1, Banafshé Larijani and Peter J. Parker (2017)

#
Vesicular PtdIns(3,4,5)P3 and Rab7 are key effectors of sea urchin zygote nuclear membrane fusion.
2017. Published by The Company of Biologists Ltd Journal of Cell Science (2017) 130, 444-452 doi:10.1242/jcs.193771

M.G.Lete, R.B.Byrne, A.Alonso, D.Poccia, B.Larijani. (2017)

#
Functional proteomic biomarkers in cancer
Ann N Y Acad Sci. 1346(1):1-6 doi: 10.1111/nyas.12749

Larijani B, Perani M, Alburai’si K, Parker PJ. (2015)

#
Conservation of proteo-lipid nuclear membrane fusion machinery during early embryogenesis.
Nucleus 5(5):441-8. doi: 10.4161/nucl.34422.

Byrne RD, Veeriah S, Applebee CJ, Larijani B. (September 2014)

#
Akt/PKB activation in human primary breast carcinoma is a poor prognostic marker: determined by high throughput coincidence amplified-FRET.
S.Veeriah, P.Leboucher, J.de Naurois, N.Jethwa, E.Nye, T.Bunting, R.Stone, V.Calleja, G.Stamp, S.Jeffrey, P.J.Parker, B.Larijani (2014)
#
HER2 oncogenic function escapes EGFR tyrosine kinase inhibitors via activation of alternative HER receptors in breast cancer cells.
PLoS One. Aug 6;3 (8):e2881

Kong A, Calleja V, Leboucher P, Harris A, Parker PJ, Larijani B. (2008)

#
Prognostic value of an activation state marker for epidermal growth factor receptor in tissue microarrays of head and neck cancer.
Cancer Res. 2006 Mar 1;66(5):2834-43.

Kong A, Leboucher P, Leek R, Calleja V, Winter S, Harris A, Parker PJ, Larijani B. (2006)